Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPO107 |
Synonyms | |
Therapy Description |
CPO107 is a bispecific fusion protein consisting ofatumumab, an anti-CD20 antibody, linked to signal regulatory protein alpha (SIRPalpha), which targets CD20 and CD47 expressed on tumor cells, potentially leading to antibody-dependent and complement-mediated tumor cell cytotoxicity and increased tumor cell phagocytosis and anti-tumor T-cell response (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPO107 | CPO 107|CPO-107|JMT601 | CD20 Antibody 24 CD47 Antibody 31 | CPO107 is a bispecific fusion protein consisting ofatumumab, an anti-CD20 antibody, linked to signal regulatory protein alpha (SIRPalpha), which targets CD20 and CD47 expressed on tumor cells, potentially leading to antibody-dependent and complement-mediated tumor cell cytotoxicity and increased tumor cell phagocytosis and anti-tumor T-cell response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |